Lawyers Accuse J&J and Bayer of Withholding Xarelto Study Data
Lawyers for patients suing Johnson & Johnson and Bayer over severe bleeding injuries caused by the blockbuster blood thinner Xarelto say the drug makers failed to provide clinical trial data, the New York Times reported.
Documents filed in court say a re-analysis conducted by Duke published by the New England Medical Journal of Medicine was missing key information that could have affected clinical trial data comparing Xarelto to warfarin in its 2011 ROCKET-AF study. J&J and Bayer stayed silent and helped deceive editors of the journal, lawyers said.
The trial in question compared the safety of Xarelto and warfarin. Specifically, it collected data on the number of strokes and bleeding events experienced by patients taking one drug or the other. According to the study results, both Xarelto and warfarin had the same risk of bleeding, but J&J and Bayer’s drug showed fewer incidents of bleeding in the brain and fatal bleeding.
TriMark Legal Funding provides non-recourse pre-settlement and post-settlement Xarelto lawsuit loans to injured plaintiffs nationwide.
This post originally appeared here: https://www.drugwatch.com/news/2016/03/09/lawyers-accuse-jj-bayer-withholding-xarelto-study-data/
Click here to see the full original article.